Buserelin
Back to searchMolecule Structure
Scientific Name
Buserelin
Description of the Drug
Buserelin is a LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06719
http://www.drugbank.ca/drugs/DB06719
Brand Name(s)
Suprecur, Suprefact
Company Owner(s)
Not Available
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | SINGLE PROTEIN | AGONIST | CHEMBL1855 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19459955 | SCHEMBL19409318 | SCHEMBL13354 |
| DrugBank | DB06719 | ||
| PubChem: Thomson Pharma | 14792674 | 16007031 | 16901273 |
| PubChem | 50225 | ||
| Nikkaji | J14.642K | ||
| DrugCentral | 436 | ||
| ChemicalBook | CB9287695 | CB6287694 | |
| Guide to Pharmacology | 3860 | ||
| rxnorm | BUSERELIN | BUSERELIN ACETATE | |
| ChEBI | 135907 |
